...
首页> 外文期刊>Epigenomics >CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer
【24h】

CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer

机译:CDH1,DLEC1和SFRP5甲基化板作为先进上皮性卵巢癌的预后标志物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Aim: To investigate the CDH1, DLEC1 and SFRP5 gene methylation panel for advanced epithelial ovarian carcinoma (EOC). Materials & methods: One hundred and seventy-seven advanced EOC specimens were evaluated by methylation-specific PCR. We also used The Cancer Genome Atlas dataset to evaluate the panel. Results: The presence of two or more methylated genes was significant in recurrence (hazard ratio [HR]: 1.91 [1.33-2.76]; p = 0.002) and death (HR: 1.96 [1.26-3.06]; p = 0.006) in our cohort. In The Cancer Genome Atlas dataset, the presence of two or three methylated genes was significant in death (HR: 1.59 [1.15-2.18]; p = 0.0047) and close to the significance level in recurrence (HR: 1.37 [0.99-1.88]; p = 0.058). Conclusion: The CDH1, DLEC1 and SFRP5 methylation panel is a potential prognostic biomarker for advanced EOC.
机译:目的:用于研究晚期上皮细胞卵巢癌(EOC)的CDH1,DLEC1和SFRP5基因甲基化板。 材料和方法:通过甲基化的PCR评估一百七十七个先进的EOC标本。 我们还使用癌症基因组Atlas数据集来评估面板。 结果:两种或更多种甲基化基因的存在在复发中显着(危险比[HR]:1.91 [1.33-2.76]; P = 0.002)和死亡(HR:1.96 [1.26-3.06]; P = 0.006) 队列。 在癌症基因组Atlas数据集中,死亡中存在两种或三种甲基化基因的存在(HR:1.59 [1.15-2.18]; p = 0.0047)并接近复发中的显着水平(HR:1.37 [0.99-1.88] ; p = 0.058)。 结论:CDH1,DLEC1和SFRP5甲基化面板是高原潜在预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号